Field Alert Report - FDA Form 3331

Justification Memo for 83C Change Request 11-13-14.doc

FDA Approval to Market a New Drug

Field Alert Report - FDA Form 3331

OMB: 0910-0001

Document [doc]
Download: doc | pdf

Field Alert Report - Form FDA 3331

(Currently approved under OMB Control Number 0910-0001)


CHANGE REQUEST (83-C)

Date: November 12, 2014



We are proposing changes to Form FDA 3331. This form is available for paper-based submissions, and as an automated form that has XML activation and functionality with a submit button that generates an email to send the form to FDA in XML format.

We are requesting the following revisions to the reporting section at the bottom of the form:

  1. A field would be added for the applicant to report their FEI or DUNS number. This number is already known to the firm.

  2. A field would be added for the applicant to report a contact email address. This information is already known to the firm.

We are also requesting layout changes to existing fields within the form. For example, Field 1 “NDA/ANDA number” will be Field 3 in the revised form. Field 5 “Firm name and Address where the problem occurred” will be Field 1 in the revised form.

We are also requesting functionality changes to the fields on the automated version of the form to enable expansion of the fields as information is added by the applicant.

We currently have OMB approval for 8 hours for applicants to prepare and submit this form to FDA (0910-0001). The additional time resulting from these proposed revisions (i.e., adding the DUNS or FEI number and an email address) would be approximately one minute. In addition, any additional time that may be needed for applicants to become familiar with the layout and functionality changes will be offset by the savings in time because applicants will no longer have to prepare and submit attachments to the form.

The OMB NOA dated 8/21/2014 should be changed as follows:


List of ICs

IC Title

Form No.

Form Name

CFR Citation

314.50 (a), (b), (c), (d), (e), (f), and (k) [356h]




[356h

356h

Application to Market a New or Abbreviated New Drug or Biologic for Human Use

21 CFR 314.50

314.50(i) and 314.94(a)(12)



21 CFR 314.50 (i), 21 CFR

314.94(a)(12)

314.50(j)



21 CFR 314.50(j)

314.52 and 314.95



21 CFR 314.52, 21 CFR

314.95

314.60



21 CFR 314.60

314.65



21 CFR 314.65

314.70 and 314.71



21 CFR 314.70, 21 CFR

314.71

314.72



21 CFR 314.72

314.81(b)(1) [3331]



21 CFR 314.81(b)(1)

314.81(b)(2) [2252]



21 CFR 314.81(b)(2)

314.81(b)(3)(i) [2253]



21 CFR 314.81(b)(3)(i)

314.94(a)(1)-(11) and (d)



21 CFR 314.94

314.96



21 CFR 314.96

314.97



21 CFR 314.97

314.99(a)



21 CFR 314.99(a)

314.101(a)



21 CFR 314.101(a)

314.107(c)



21 CFR 314.70(c)

314.107(e)



21 CFR 314.107(e)

314.107(f)



21 CFR 314.107(f)

314.110(a)(5)



21 CFR 314.110(a)(5)

314.110(c)



21 CFR 314.120(a)(5)

314.420



21 CFR 314.420

314.81(B)(2)

[3331]

3331

NDA Field Alert Report

21 CFR 314.81 (B) (2)









2



File Typeapplication/msword
AuthorQuiros, Simonne M
Last Modified ByMizrachi, Ila
File Modified2014-11-13
File Created2014-11-12

© 2024 OMB.report | Privacy Policy